Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers.

Birkbak NJ, Li Y, Pathania S, Greene-Colozzi A, Dreze M, Bowman-Colin C, Sztupinszki Z, Krzystanek M, Diossy M, Tung N, Ryan PD, Garber JE, Silver DP, Iglehart JD, Wang ZC, Szuts D, Szallasi Z, Richardson AL.

Ann Oncol. 2018 Apr 1;29(4):903-909. doi: 10.1093/annonc/mdy049.

2.

Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.

Ni J, Ramkissoon SH, Xie S, Goel S, Stover DG, Guo H, Luu V, Marco E, Ramkissoon LA, Kang YJ, Hayashi M, Nguyen QD, Ligon AH, Du R, Claus EB, Alexander BM, Yuan GC, Wang ZC, Iglehart JD, Krop IE, Roberts TM, Winer EP, Lin NU, Ligon KL, Zhao JJ.

Nat Med. 2016 Jul;22(7):723-6. doi: 10.1038/nm.4120. Epub 2016 Jun 6.

3.

Identification of genes responsible for RelA-dependent proliferation arrest in human mammary epithelial cells conditionally expressing RelA.

Kochupurakkal BS, Iglehart JD.

Genom Data. 2015 Nov 27;7:92-3. doi: 10.1016/j.gdata.2015.11.022. eCollection 2016 Mar.

4.

Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020).

Nakhlis F, Gilmore L, Gelman R, Bedrosian I, Ludwig K, Hwang ES, Willey S, Hudis C, Iglehart JD, Lawler E, Ryabin NY, Golshan M, Schnitt SJ, King TA.

Ann Surg Oncol. 2016 Mar;23(3):722-8. doi: 10.1245/s10434-015-4922-4. Epub 2015 Nov 5.

5.

RelA-Induced Interferon Response Negatively Regulates Proliferation.

Kochupurakkal BS, Wang ZC, Hua T, Culhane AC, Rodig SJ, Rajkovic-Molek K, Lazaro JB, Richardson AL, Biswas DK, Iglehart JD.

PLoS One. 2015 Oct 13;10(10):e0140243. doi: 10.1371/journal.pone.0140243. eCollection 2015.

6.

CDK7-dependent transcriptional addiction in triple-negative breast cancer.

Wang Y, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, Yuzugullu H, Von T, Li H, Lin Z, Stover DG, Lim E, Wang ZC, Iglehart JD, Young RA, Gray NS, Zhao JJ.

Cell. 2015 Sep 24;163(1):174-86. doi: 10.1016/j.cell.2015.08.063.

7.

Monitoring repair of UV-induced 6-4-photoproducts with a purified DDB2 protein complex.

Dreze M, Calkins AS, Gálicza J, Echelman DJ, Schnorenberg MR, Fell GL, Iwai S, Fisher DE, Szüts D, Iglehart JD, Lazaro JB.

PLoS One. 2014 Jan 28;9(1):e85896. doi: 10.1371/journal.pone.0085896. eCollection 2014.

8.

NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth.

Bailey ST, Miron PL, Choi YJ, Kochupurakkal B, Maulik G, Rodig SJ, Tian R, Foley KM, Bowman T, Miron A, Brown M, Iglehart JD, Debajit KB.

Mol Cancer Res. 2014 Mar;12(3):408-420. doi: 10.1158/1541-7786.MCR-13-0206-T. Epub 2013 Dec 6.

9.

Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.

Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.

PLoS One. 2013 Nov 12;8(11):e80023. doi: 10.1371/journal.pone.0080023. eCollection 2013.

10.

Nourseothricin N-acetyl transferase: a positive selection marker for mammalian cells.

Kochupurakkal BS, Iglehart JD.

PLoS One. 2013 Jul 4;8(7):e68509. doi: 10.1371/journal.pone.0068509. Print 2013.

11.

DNA damage-induced inhibition of rRNA synthesis by DNA-PK and PARP-1.

Calkins AS, Iglehart JD, Lazaro JB.

Nucleic Acids Res. 2013 Aug;41(15):7378-86. doi: 10.1093/nar/gkt502. Epub 2013 Jun 17.

12.

Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response.

Jeselsohn RM, Werner L, Regan MM, Fatima A, Gilmore L, Collins LC, Beck AH, Bailey ST, He HH, Buchwalter G, Brown M, Iglehart JD, Richardson A, Come SE.

PLoS One. 2013 May 31;8(5):e64225. doi: 10.1371/journal.pone.0064225. Print 2013.

13.

Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.

Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, DeFazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD; Australian Ovarian Cancer Study Group, Matulonis UA.

Clin Cancer Res. 2012 Oct 15;18(20):5806-15. doi: 10.1158/1078-0432.CCR-12-0857. Epub 2012 Aug 21.

14.

Large needle core biopsy of atypical ductal hyperplasia: results of surgical excision.

Dominici L, Liao GS, Brock J, Iglehart JD, Lotfi P, Meyer J, Pandalai P, Golshan M.

Breast J. 2012 Sep;18(5):506-8. doi: 10.1111/j.1524-4741.2012.01296.x. Epub 2012 Aug 17. No abstract available.

PMID:
22897750
15.

The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.

Utermark T, Rao T, Cheng H, Wang Q, Lee SH, Wang ZC, Iglehart JD, Roberts TM, Muller WJ, Zhao JJ.

Genes Dev. 2012 Jul 15;26(14):1573-86. doi: 10.1101/gad.191973.112.

16.

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.

Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL.

Cancer Discov. 2012 Apr;2(4):366-375. doi: 10.1158/2159-8290.CD-11-0206. Epub 2012 Mar 22. Erratum in: Cancer Discov. 2013 Aug;3(8):952.

17.

BEAMing up personalized medicine: mutation detection in blood.

Richardson AL, Iglehart JD.

Clin Cancer Res. 2012 Jun 15;18(12):3209-11. doi: 10.1158/1078-0432.CCR-12-0871. Epub 2012 May 1.

18.

DNA ends alter the molecular composition and localization of Ku multicomponent complexes.

Adelmant G, Calkins AS, Garg BK, Card JD, Askenazi M, Miron A, Sobhian B, Zhang Y, Nakatani Y, Silver PA, Iglehart JD, Marto JA, Lazaro JB.

Mol Cell Proteomics. 2012 Aug;11(8):411-21. doi: 10.1074/mcp.M111.013581. Epub 2012 Apr 24.

19.

Commentary on "The role of the breast cancer surgeon in personalized cancer care: clinical utility of the 21-gene assay".

Iglehart JD, Valero MG.

Am J Surg. 2012 Jun;203(6):759-60. doi: 10.1016/j.amjsurg.2011.09.030. Epub 2012 Apr 10. No abstract available.

PMID:
22494880
20.

The amplified cancer gene LAPTM4B promotes tumor growth and tolerance to stress through the induction of autophagy.

Li Y, Iglehart JD, Richardson AL, Wang ZC.

Autophagy. 2012 Feb 1;8(2):273-4. doi: 10.4161/auto.8.2.18941. Epub 2012 Feb 1.

21.

Should a sentinel node biopsy be performed in patients with high-risk breast cancer?

Westover KD, Westover MB, Winer EP, Richardson AL, Iglehart JD, Punglia RS.

Int J Breast Cancer. 2011;2011:973245. doi: 10.4061/2011/973245. Epub 2011 Aug 10.

22.

Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells.

Li Y, Zhang Q, Tian R, Wang Q, Zhao JJ, Iglehart JD, Wang ZC, Richardson AL.

Cancer Res. 2011 Dec 15;71(24):7481-9. doi: 10.1158/0008-5472.CAN-11-0940. Epub 2011 Oct 28.

23.

Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates?

Barkley C, Burstein H, Smith B, Bellon J, Wong J, Gadd M, Taghian A, Winer E, Iglehart JD, Harris J, Golshan M.

Breast J. 2012 Jan-Feb;18(1):23-7. doi: 10.1111/j.1524-4741.2011.01178.x. Epub 2011 Oct 21.

PMID:
22017599
24.

Therapeutic implications of GIPC1 silencing in cancer.

Chittenden TW, Pak J, Rubio R, Cheng H, Holton K, Prendergast N, Glinskii V, Cai Y, Culhane A, Bentink S, Schwede M, Mar JC, Howe EA, Aryee M, Sultana R, Lanahan AA, Taylor JM, Holmes C, Hahn WC, Zhao JJ, Iglehart JD, Quackenbush J.

PLoS One. 2010 Dec 30;5(12):e15581. doi: 10.1371/journal.pone.0015581.

25.

Molecular imaging of the breast.

Birdwell RL, Mountford CE, Iglehart JD.

Radiol Clin North Am. 2010 Sep;48(5):1075-88. doi: 10.1016/j.rcl.2010.07.017.

PMID:
20868901
26.

PIK3CA mutations in in situ and invasive breast carcinomas.

Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S, Iglehart JD, Dillon D, Allred DC, Macconaill L, Gelman R, Polyak K.

Cancer Res. 2010 Jul 15;70(14):5674-8. doi: 10.1158/0008-5472.CAN-08-2660. Epub 2010 Jun 15.

27.

Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis.

Qiao M, Wang Y, Xu X, Lu J, Dong Y, Tao W, Stein J, Stein GS, Iglehart JD, Shi Q, Pardee AB.

Mol Cell. 2010 May 28;38(4):512-23. doi: 10.1016/j.molcel.2010.03.017.

28.

Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer.

Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL, Wang ZC.

Nat Med. 2010 Feb;16(2):214-8. doi: 10.1038/nm.2090. Epub 2010 Jan 24.

29.

NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.

Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC.

J Natl Compr Canc Netw. 2009 Sep;7 Suppl 6:S1-S21; quiz S22-3. Review.

PMID:
19755043
30.

SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis.

Cheng H, Liu P, Wang ZC, Zou L, Santiago S, Garbitt V, Gjoerup OV, Iglehart JD, Miron A, Richardson AL, Hahn WC, Zhao JJ.

Sci Signal. 2009 Jul 21;2(80):ra35. doi: 10.1126/scisignal.2000369.

31.

Molecular imaging of the breast.

Birdwell RL, Mountford CE, Iglehart JD.

AJR Am J Roentgenol. 2009 Aug;193(2):367-76. doi: 10.2214/AJR.09.3079.

PMID:
19620433
32.

Synthetic lethality--a new direction in cancer-drug development.

Iglehart JD, Silver DP.

N Engl J Med. 2009 Jul 9;361(2):189-91. doi: 10.1056/NEJMe0903044. Epub 2009 Jun 24. No abstract available.

PMID:
19553640
33.

Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy.

Nunes RA, Li X, Kang SP, Burstein H, Roberts L, Carney W, Blackwell K, Ryan P, Borges V, Iglehart JD, Friedman P, Harris LN.

Int J Biol Markers. 2009 Jan-Mar;24(1):1-10.

PMID:
19404916
34.
35.

Risk prediction models with incomplete data with application to prediction of estrogen receptor-positive breast cancer: prospective data from the Nurses' Health Study.

Rosner B, Colditz GA, Iglehart JD, Hankinson SE.

Breast Cancer Res. 2008;10(4):R55. doi: 10.1186/bcr2110. Epub 2008 Jul 3.

36.

Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival.

Bafford AC, Burstein HJ, Barkley CR, Smith BL, Lipsitz S, Iglehart JD, Winer EP, Golshan M.

Breast Cancer Res Treat. 2009 May;115(1):7-12. doi: 10.1007/s10549-008-0101-7. Epub 2008 Jun 26. Review.

PMID:
18581232
37.

Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells.

You F, Roberts LA, Kang SP, Nunes RA, Dias C, Iglehart JD, Solomon NA, Friedman PN, Harris LN.

J Hematol Oncol. 2008 May 28;1:2. doi: 10.1186/1756-8722-1-2.

38.

Predicting features of breast cancer with gene expression patterns.

Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL.

Breast Cancer Res Treat. 2008 Mar;108(2):191-201. doi: 10.1007/s10549-007-9596-6. Epub 2007 May 22.

PMID:
18297396
39.

Circulating colony stimulating factor-1 and breast cancer risk.

Tamimi RM, Brugge JS, Freedman ML, Miron A, Iglehart JD, Colditz GA, Hankinson SE.

Cancer Res. 2008 Jan 1;68(1):18-21. doi: 10.1158/0008-5472.CAN-07-3234.

40.

Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes.

Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA.

Cancer Cell. 2007 Aug;12(2):160-70.

41.

Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?

Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M.

J Surg Oncol. 2007 Nov 1;96(6):474-80.

PMID:
17640031
42.
43.

Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation.

Qiao M, Iglehart JD, Pardee AB.

Cancer Res. 2007 Jun 1;67(11):5293-9.

44.

Serial transplantation of NMU-induced rat mammary tumors: a model of human breast cancer progression.

Chan MM, Lu X, Merchant FM, Iglehart JD, Miron PL.

Int J Cancer. 2007 Aug 1;121(3):474-85.

45.

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.

Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP.

Clin Cancer Res. 2007 Feb 15;13(4):1198-207.

46.

Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.

Chang SB, Miron P, Miron A, Iglehart JD.

J Surg Res. 2007 Mar;138(1):37-44. Epub 2006 Nov 15.

PMID:
17109887
47.

Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery.

Shi Q, Harris LN, Lu X, Li X, Hwang J, Gentleman R, Iglehart JD, Miron A.

J Proteome Res. 2006 Nov;5(11):2947-55.

PMID:
17081046
48.

Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.

Biswas DK, Iglehart JD.

J Cell Physiol. 2006 Dec;209(3):645-52. Review.

PMID:
17001676
49.

Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer.

Ganesan S, Richardson AL, Wang ZC, Iglehart JD, Miron A, Feunteun J, Silver D, Livingston DM.

Cold Spring Harb Symp Quant Biol. 2005;70:93-7.

PMID:
16869742
50.

Supplemental Content

Loading ...
Support Center